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Introduction
Melanoma regression, either through adoptive T cell therapy (ATT) 
or T cell checkpoint inhibitors blocking CTLA4 or PD-1/PD-1 ligand, 
correlated with increased frequencies of neoantigen-specific T cells, 
as deduced from cancer genome sequencing (1–3). However, the 
potential of neoantigen-specific T cells to induce tumor regression 
is largely unexplored (4). Neoepitopes may vary in their suitability as 
target (5), but identifying suitable epitopes remains difficult because 
in vitro analysis of T cells often cannot predict in vivo efficacy (6). 
Similarly, although T cells against neoepitopes are not subjected to 
central tolerance mechanisms, their fate in cancer-bearing individu-
als is unclear, as is the functional quality of T cell receptors (TCRs) 
obtained from individuals with cancer. Therefore, we investigated 
different human melanoma mutations as targets for TCR gene ther-
apy in a syngeneic HLA-A2–transgenic cancer model in which spe-
cific immune recognition relies on human molecules (MHC, TCR, 
and tumor antigen), while cellular components (tumor cells, T cells 
and host) are of mouse origin. Using the model, we also compared a 
native melanoma epitope with its anchor-modified variant to deter-
mine whether experiments using peptide analogs are of predictive 
value for the design of clinical applications.
Results and Discussion
Three cancer-driving mutations have been described in the 
cyclin-dependent kinase 4 (CDK4) gene of human melanomas, 
substituting arginine at position 24, which is critical for binding 
to p16INK4A (R24C, R24H, and R24L) (7–9). Since these mutations 
modify an HLA-A2 anchor position, the CDK4 peptide becomes 
antigenic and is recognized by specific T cells (7, 10) if the muta-
tion stabilizes the peptide:MHC complex. We isolated the TCR 
14/35 from a T cell clone, which was established by culture with 
the autologous melanoma cell line SKMEL-29 bearing the R24C 
mutation (ref. 7 and Figure 1A). The 14/35-transduced human 
T cells (Figure 1B) recognized HLA-A2+ SKMEL-29 (R24C) 
and WM-902B melanoma cells bearing the R24L mutation, as 
indicated by IFN-γ release and cytotoxic activity, by measur-
ing CD107a expression (Figure 1, A and C, and Supplemental 
Figure 1A; supplemental material available online with this 
article; doi:10.1172/JCI83465DS1). In contrast, 14/35-trans-
duced human T cells did not recognize SKMEL-37, containing 
the R24H mutation (Figure 1, A and C, and Supplemental Fig-
ure 1A), which probably does not support MHC binding and 
was therefore excluded from further analysis. The 624MEL-38 
melanoma cells, containing wild-type CDK4, were also not rec-
ognized (Figure 1, A and C, and Supplemental Figure 1A). West-
ern blot analysis confirmed expression of CDK4 in all human 
melanoma cell lines (Supplemental Figure 2). The antitumor 
response of 14/35-transduced T cells was similar to that of T 
cells modified with a tyrosinase-specific TCR that was derived 
from a nontolerant T cell repertoire (anti-TYR; ref. 11 and Fig-
ure 1, B and C). R24L, but not R24C or R24H, is predicted to 
increase the affinity of the mutated CDK4 peptide to HLA-A2 
(Table 1). However, the binding prediction of the cysteine-con-
taining peptide R24C is problematic, because algorithms do not 
account for unavoidable oxidation and cysteinylation during 
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ribosome entry site [IRES] sequence to GFP) were expressed in 
mouse MC703 tumor cells. The fibrosarcoma MC703 was gen-
erated in an HLA-A2–transgenic mouse (HHD, chimeric HLA-
A2/H-2Db) (13) and expressed HHD (Figure 1E). The tumor cells 
MC703-R24C and MC703-R24L expressed similar amounts 
of mutant CDK4 (Figure 1F) and were similarly recognized by 
HHD-derived T cells that were transduced with 14/35 (Figure 1, 
G and H, and Supplemental Figure 1B). Transgenic expression 
of CDK4 variants in MC703 tumor cells was somewhat higher if 
compared with the native expression in human melanoma cell 
lines (Supplemental Figure 2). In vitro analysis of both CDK4 
assays. Furthermore, it was suggested that the highly oxidiz-
able sulfur residue in cysteine may contribute to MHC binding 
and could function as “pseudo”-anchor residue (5), an excep-
tion that is not considered when evaluating the R24C peptide in 
silico (12). Experimentally, 14/35-transduced human T cells rec-
ognized both the R24C and the R24L peptides, and differences 
were only detectable at low peptide concentrations (Figure 1D). 
This does not reflect the large differences obtained from MHC-
binding predictions. To analyze the quality of both neoepitopes 
as therapeutic targets in a model of large established tumors, 
the mutant variants of the CDK4 gene (linked by an internal 
Figure 1. In vitro analysis suggests suitability of 2 different CDK4 epitopes as targets for TCR gene therapy. (A) Nucleotide and amino acid sequences 
of CDK423–25 in melanoma cell lines. Mutations in codon 24 are indicated. (B) Percentages of human CD8+ and CD8– peripheral blood lymphocytes (PBLs) 
expressing 14/35 or a tyrosinase-specific TCR (anti-TYR). (C and D) IFN-γ secretion of human 14/35-expressing PBLs after coculture with (C) indicated 
melanoma cells or (D) T2 cells loaded with graded amounts of peptide (ACD, CDK423–32(24C); ALD, CDK423–32(24L); ARD, CDK423–32). WM-902B+A2 is an HLA-A2–
transfected variant of HLA-A2– WM-902B melanoma cells. PBLs expressing a tyrosinase-specific TCR and/or unmodified PBLs were used as control. Data 
are means of duplicates ± mean deviation and representative of independent experiments (n = 4 [C]; n = 2 [D]) using PBLs of different donors. (E) HHD 
(HLA-A2) expression in MC703 cancer cells. (F) Antigen (GFP) expression in MC703-R24C and MC703-R24L tumor cells. (G) Percentage of 14/35-express-
ing HHD T cells (TCRvβ1) 10 days after retroviral transduction. (H) IFN-γ secretion of 14/35-expressing HHD T cells after coculture with MC703-R24C, 
MC703-R24L, and MC703-TYR tumor cells. HHD T cells either unmodified or expressing a tyrosinase-specific TCR were used as control. Data are means of 
duplicates ± mean deviation and representative of 3 independent experiments. ND, not detectable.
Table 1. HLA-A2 binding prediction for CDK4 and MART-1 peptides
Designation Abbreviation Epitope sequence NetMHCA IEDBA References
CDK423–32 ARD ARDPHSGHFV 17871 15222
CDK423–32(24C) R24C/ACD ACDPHSGHFV 10279 12008 7
CDK423–32(24H) R24H AHDPHSGHFV 18698 15083 8
CDK423–32(24L) R24L/ALD ALDPHSGHFV 55 184 9
MART-127–35 AAG AAGIGILTV 2498 1429 16
MART-126–35(27L) ELA ELAGIGILTV 137 146 18
Computer algorithms for MHC I binding prediction are available as follows: NetMHC (http://www.cbs.dtu.dk/services/NetMHC/); IEDB Analysis Resource 
(http://tools.immuneepitope.org/mhci/). AValues indicate predicted IC50 (correct as of 12/07/15). Mutations or modifications are in bold.
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mini genes improved recognition of MC703 cells, while the rel-
ative difference in recognition of both neoepitopes remained 
unchanged (Supplemental Figure 5). Under these limiting con-
ditions, a better recognition of the R24L compared with the 
R24C mutation became clearly apparent. However, tumors 
expressing increased amounts of the R24C epitope still pro-
gressed after transfer of 14/35-TE (Figure 2C and Supplemen-
tal Table 1). In contrast, all R24L epitope–expressing tumors 
were eradicated (Figure 2D), suggesting that R24L is a rejec-
tion epitope in human melanoma if sufficient peptide:MHC I 
complexes are present on the tumor cells.
To investigate differences in therapeutic outcome when tar-
geting R24C or R24L, we followed 14/35-TE after transfer into 
mice bearing MC703-R24C or MC703-R24L tumors. On day 7 
after ATT, high numbers of CD8+ 14/35-TE were detected when 
tumors expressed the R24L mutation (Figure 2E), while T cell 
expansion was significantly impaired when tumors expressed 
R24C (Figure 2, E and F). We asked whether 14/35-transduced 
CD4+ T cells contributed to the response to R24L. However, 
only CD8+ but not CD8– 14/35-TE expanded in vivo in response 
to R24L (Supplemental Figure 6A). Similarly, the total number 
of CD8+ but not CD8– 14/35-TE increased during the course 
of ATT (Supplemental Figure 6, B and C). Furthermore, only 
CD8+ but not CD4+ 14/35-transduced HHD T cells (Supple-
mental Figure 6D) secreted IFN-γ and IL-2 after incubation 
with MC703 target cells (Supplemental Figure 6, E and F), sug-
mutations, using human 14/35-transduced T cells and human 
melanoma cells that naturally express the CDK4 mutations or 
T cells and tumor cells from HHD mice, suggested R24C and 
R24L as relevant targets for specific T cells.
For in vivo analysis, we used HHD Rag–/– mice lacking 
mouse MHC I molecules, B cells, and T cells to focus on a 
single human MHC I molecule and to exclude endogenous T 
cell responses. HHD Rag–/– mice bearing large tumors (grown 
for 3 to 4 weeks, having an average diameter of 9–10 mm) 
were treated with 14/35-transduced effector T cells derived 
from HHD mice (14/35-TE). Remarkably, 14/35-TE did not 
even delay progression of MC703-R24C tumors (Figure 2A 
and Supplemental Table 1), while large MC703-R24L tumors 
regressed upon 14/35-TE treatment (Figure 2B). However, 
probably because expression of HHD in transgenic mice is 
low (Supplemental Figure 3) and the antigen expression level 
is critical for successful ATT (14), tumors eventually relapsed. 
We repeated the experiments using MC703 cells that express 
minigenes encoding 3 copies of the R24C (MC703-ACD) or the 
R24L (MC703-ALD) epitope (Supplemental Figure 4, A and B) 
to compensate for low MHC expression. Both cancer cell lines 
were similarly recognized by 14/35-TE in vitro (Supplemental 
Figure 4C). To determine the improvement in target cell recog-
nition by increasing the amount of epitopes on the cancer cells, 
we titrated the number of antigen-expressing MC703 cells 
necessary to stimulate 14/35-transduced HHD T cells. Using 
Figure 2. Neoepitope quality determines rejection of large HLA-A2+ tumors by TCR gene therapy. (A–D) HHD Rag–/– mice bearing established 
MC703-R24C (A, n = 5, average tumor size: 214 ± 90 mm3; mean values ± SD), MC703-R24L (B, n = 7, 606 ± 304 mm3), MC703-ACD (C, n = 7, 317 
± 155 mm3), or MC703-ALD (D, n = 6, 315 ± 100 mm3) tumors were treated with 14/35-TE (adjusted to 1 × 106 CD8+ 14/35-TE). Tumor-bearing HHD 
Rag–/– mice that received T cells expressing a tyrosinase-specific TCR are shown as control. Tumor growth in these animals and untreated mice was 
comparable. (E and F) Number (E, day 7) and fold expansion (F, from day 4 to 7) of CD8+ 14/35-TE after ATT of mice bearing MC703-R24C (n = 5) or 
MC703-R24L tumors (n = 7) shown in A and B. Data shown in E are representative for the analysis of 5 (R24C) and 7 samples (R24L). Independent 
2-sample t test was used to compare data sets in F. (G) Blood samples were collected on days 4, 7, 14, and 28 after ATT of mice bearing MC703-R24C 
(n = 4) or -R24L tumors (n = 7), and serum was analyzed for IFN-γ content. Factor change from baseline was deduced from untreated mice (2 ± 1  
pg/ml, mean values ± SD, n = 5). (H) Peak values in blood determined for the number of CD8+ 14/35-TE and concentration of IFN-γ. Mean ± SD 
(R24C: n = 4, R24L: n = 7) is shown.
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sent an unprecedented case of the stochastic nature of creating 
immuno genic neoepitopes of dramatically different quality. It is 
likely that both neoepitopes were selected for their oncogenicity 
and were recognized on the autologous tumor, leading to expan-
sion of a specific T cell response. In the case of CDK4R24C, T cells 
were clonally expanded on the autologous melanoma cells (7), 
while in the case of CDK4R24L, neoepitope-specific T cells were 
detected at low frequency within the tumor-infiltrating lympho-
cytes (10). Both CDK4 neoepitopes were naturally expressed 
by human melanoma cells and stimulated specific T cells in 
vitro. Also in common, T cells to both neoepitopes neither pre-
vented melanoma nor selected escape variants in the respective 
patient, which is compatible with data from a sporadic cancer 
model (24). Paradoxically, the mutant CDK4-specific TCR, 
raised against the R24C mutation, was only effective against 
R24L. Given the generally high mutation load in human mela-
noma, we hypothesize that deviation of the T cell response to the 
R24C mutation might deter the T cell response to other reces-
sive neoepitopes (25). Thus, our data may give one explanation 
for the differential response of patients to checkpoint inhibi-
tors despite similar mutational load. We note, however, that the 
R24L mutation needed to be expressed in sufficient amounts 
to prevent tumor recurrence, as suggested (14). Data on target-
ing MART-1 confirmed the difficulty of predicting therapeutic 
efficacy based on in vitro analysis and the importance of high 
peptide:MHC affinity (6). The results are at variance with clini-
cal trials in melanoma patients with the DMF5 TCR that showed 
some efficacy (26). However, in these trials, high-dose IL-2 
was additionally applied, which alone can achieve responses in 
16% of the patients (27). Alternatively, low MHC I expression in 
HHD-transgenic cells could have impeded TCR gene therapy. 
The current syngeneic model using large established tumors 
and only the T cell recognition system that is of human origin 
allows identification of (un)suitable epitopes, which, in turn, 
may help to improve clinical success rates.
gesting that therapeutic effects can be ascribed to CD8+ 14/35-
TE. Next, we analyzed serum levels of IFN-γ, a critical effector 
cytokine for tumor rejection (15), to obtain evidence for func-
tional T cell activation in vivo. The concentration of IFN-γ in 
blood correlated with the number of CD8+ 14/35-TE and was 
higher if tumors expressed the R24L mutation (Figure 2, G and 
H). This is in line with the observation that 14/35-transduced 
HHD T cells showed higher sensitivity for tumor cells express-
ing the R24L mutation (Supplemental Figure 5), which likely 
improved T cell activation/expansion in vivo and supported 
IFN-γ production in lymphopenic tumor-bearing mice.
To confirm the critical role of the target epitope in ATT, we 
employed native and anchor-modified melan-A (MART-1) epi-
topes. The MART-1 nonamer peptide AAGIGILTV (AAG) (16) 
is assumed to be relevant in HLA-A2+ melanoma (17), whereas 
MART-1–specific T cells are often analyzed using the decam-
eric peptide ELAGIGILTV (ELA) (18). ELA is modified from its 
original sequence in position 2 to improve MHC binding (Table 
1). Biochemical analyses showed that the MART-1–specific TCR 
DMF5 engages both ligands similarly, with only minor differ-
ences in affinity (19). To evaluate the potential of DMF5-trans-
duced T cells to eliminate AAG-expressing cancer, we gener-
ated MC703 cells expressing minigenes that encode either AAG 
(MC703-AAG) or ELA epitopes (MC703-ELA, Figure 3A). Both 
cancer cell lines were equally recognized by DMF5-transduced 
HHD T cells in vitro (Figure 3, B and C). However, the growth of 
MC703-AAG tumors was not influenced by ATT using DMF5-
TE (Figure 3D and Supplemental Table 1), while MC703-ELA 
tumors were rejected (Figure 3E). In a manner comparable to 
the differences in the recognition of the 2 CDK4 neoepitopes by 
14/35-TE, CD8+ DMF5-TE expanded in mice bearing ELA- but 
not AAG-expressing MC703 tumors (Figure 3F).
In mice and humans, effective T cell responses seem pri-
marily directed against somatically mutated neoepitopes 
(20–23). The 2 CDK4 mutations in human melanoma repre-
Figure 3. The anchor-modified but not the 
native MART-1 epitope elicits tumor rejection by 
TCR gene therapy. (A) Antigen (GFP) expression 
in MC703-AAG, MC703-ELA, and MC703-YMD 
tumor cells. (B) Percentage of DMF5-expressing 
(A2/Kb:ELA) HHD T cells 5 days after retroviral 
transduction. (C) IFN-γ secretion of DMF5-
expressing HHD T cells after coculture with 
indicated cells. HHD T cells either unmodified 
or expressing a tyrosinase-specific TCR were 
used as control. Data are means of duplicates 
± mean deviation and are representative of 3 
independent experiments. (D and E) HHD Rag–/– 
mice bearing established MC703-AAG (D, n = 5, 
average tumor size: 224 ± 118 mm3; mean values 
± SD) or MC703-ELA tumors (E, n = 4, 245 ± 72 
mm3) were treated with DMF5-TE (adjusted to  
1 × 106 CD8+ DMF5-TE). Tumor-bearing HHD Rag
–/– 
mice that received T cells expressing a TYR-spe-
cific TCR are shown as control. (F) Fold expansion 
(from day 3 to 14) of CD8+ DMF5-TE after ATT of 
mice bearing MC703-AAG (n = 4) or MC703-ELA 
tumors (n = 4). Data sets were compared using 
independent 2-sample t tests.
The Journal of Clinical Investigation B r i e f  r e p o r t
8 5 8 jci.org   Volume 126   Number 3   March 2016
Acknowledgments
The authors thank Kordelia Hummel and Kimberley Borutta for 
excellent technical support and Gabriela Pflanz and Isabell Höft 
for animal care and breeding services. We thank Thomas Wölfel 
for providing the 14/35 clone and Bernhard Frankenberger for 
determining TCR 14/35 sequences. The work was supported by 
grants from the German Research Foundation (SFB-TR36), the 
Berlin Institute of Health (CRG-1), Deutsche Krebshilfe, Einstein-
Stiftung Berlin, and Wilhelm Sander-Stiftung.
Address correspondence to: Thomas Blankenstein, Molecular 
Immunology and Gene Therapy, Max-Delbrück-Center for Molec-
ular Medicine, Robert-Rössle-Strasse 10, 13092 Berlin, Germany. 
Phone: 49.30.94062316; E-mail: tblanke@mdc-berlin.de.
Methods
Statistics. Independent 2-sample t test was used to evaluate statistical 
differences between R24C/R24L and AAG/ELA data sets. P < 0.05 
was considered significant, P < 0.01 highly significant.
Study approval. All animal experiments were performed accord-
ing to institutional and national guidelines, after approval by the 
responsible authority (Landesamt für Gesundheit und Soziales, Ber-
lin). Blood collection from healthy human donors was done after prior 
informed consent. A complete, detailed description of all methods is 
provided in Supplemental Methods.
Author contributions
ML conducted experiments and acquired data. ML, TK, WU, and TB 
designed the research study, analyzed data, and wrote the manuscript.
 1. Robbins PF, et al. Mining exomic sequencing 
data to identify mutated antigens recognized by 
adoptively transferred tumor-reactive T cells. 
Nat Med. 2013;19(6):747–752.
 2. van Rooij N, et al. Tumor exome analysis reveals 
neoantigen-specific T-cell reactivity in an 
ipilimumab-responsive melanoma. J Clin Oncol. 
2013;31(32):e439–e442.
 3. Rizvi NA, et al. Cancer immunology. Muta-
tional landscape determines sensitivity to PD-1 
blockade in non-small cell lung cancer. Science. 
2015;348(6230):124–128.
 4. Blankenstein T, Leisegang M, Uckert W, Sch-
reiber H. Targeting cancer-specific mutations by 
T cell receptor gene therapy. Curr Opin Immunol. 
2015;33:112–119.
 5. Fritsch EF, Rajasagi M, Ott PA, Brusic V, Haco-
hen N, Wu CJ. HLA-binding properties of tumor 
neoepitopes in humans. Cancer Immunol Res. 
2014;2(6):522–529.
 6. Engels B, et al. Relapse or eradication of cancer 
is predicted by peptide-major histocompatibility 
complex affinity. Cancer Cell. 2013;23(4):516–526.
 7. Wölfel T, et al. A p16INK4a-insensitive 
CDK4 mutant targeted by cytolytic T lym-
phocytes in a human melanoma. Science. 
1995;269(5228):1281–1284.
 8. Soufir N, et al. Prevalence of p16 and CDK4 
germline mutations in 48 melanoma-prone fami-
lies in France. The French Familial Melanoma 
Study Group. Hum Mol Genet. 1998;7(2):209–216.
 9. Smalley KS, et al. Increased cyclin D1 expression 
can mediate BRAF inhibitor resistance in BRAF 
V600E-mutated melanomas. Mol Cancer Ther. 
2008;7(9):2876–2883.
 10. Kvistborg P, et al. TIL therapy broadens the 
tumor-reactive CD8(+) T cell compartment 
in melanoma patients. Oncoimmunology. 
2012;1(4):409–418.
 11. Wilde S, et al. Dendritic cells pulsed with 
RNA encoding allogeneic MHC and antigen 
induce T cells with superior antitumor activ-
ity and higher TCR functional avidity. Blood. 
2009;114(10):2131–2139.
 12. van Buuren MM, Calis JJ, Schumacher TN. High 
sensitivity of cancer exome-based CD8 T cell 
neo-antigen identification. Oncoimmunology. 
2014;3:e28836.
 13. Pascolo S, Bervas N, Ure JM, Smith AG, Lem-
onnier FA, Pérarnau B. HLA-A2.1-restricted 
education and cytolytic activity of CD8(+) T lym-
phocytes from β2 microglobulin (β2m) HLA-A2.1 
monochain transgenic H-2Db β2m double knock-
out mice. J Exp Med. 1997;185(12):2043–2051.
 14. Spiotto MT, Rowley DA, Schreiber H. Bystander 
elimination of antigen loss variants in established 
tumors. Nat Med. 2004;10(3):294–298.
 15. Blankenstein T. The role of tumor stroma in the 
interaction between tumor and immune system. 
Curr Opin Immunol. 2005;17(2):180–186.
 16. Kawakami Y, et al. Identification of the immuno-
dominant peptides of the MART-1 human 
melanoma antigen recognized by the majority 
of HLA-A2-restricted tumor infiltrating lympho-
cytes. J Exp Med. 1994;180(1):347–352.
 17. Skipper JC, et al. Mass-spectrometric evaluation 
of HLA-A*0201-associated peptides identifies 
dominant naturally processed forms of CTL 
epitopes from MART-1 and gp100. Int J Cancer. 
1999;82(5):669–677.
 18. Valmori D, et al. Enhanced generation of spe-
cific tumor-reactive CTL in vitro by selected 
Melan-A/MART-1 immunodominant peptide 
analogues. J Immunol. 1998;160(4):1750–1758.
 19. Borbulevych OY, Santhanagopolan SM, Hossain 
M, Baker BM. TCRs used in cancer gene ther-
apy cross-react with MART-1/Melan-A tumor 
antigens via distinct mechanisms. J Immunol. 
2011;187(5):2453–2463.
 20. Prehn RT, Main JM. Immunity to methylcholan-
threne-induced sarcomas. J Natl Cancer Inst. 
1957;18(6):769–778.
 21. Monach PA, Meredith SC, Siegel CT, Sch-
reiber H. A unique tumor antigen produced 
by a single amino acid substitution. Immunity. 
1995;2(1):45–59.
 22. Yadav M, et al. Predicting immunogenic 
tumour mutations by combining mass spec-
trometry and exome sequencing. Nature. 
2014;515(7528):572–576.
 23. Gubin MM, et al. Checkpoint blockade cancer 
immunotherapy targets tumour-specific mutant 
antigens. Nature. 2014;515(7528):577–581.
 24. Willimsky G, Blankenstein T. Sporadic immuno-
genic tumours avoid destruction by inducing T-cell 
tolerance. Nature. 2005;437(7055):141–146.
 25. Van Waes C, Monach PA, Urban JL, Wortzel RD, 
Schreiber H. Immunodominance deters the 
response to other tumor antigens thereby favor-
ing escape: prevention by vaccination with tumor 
variants selected with cloned cytolytic T cells in 
vitro. Tissue Antigens. 1996;47(5):399–407.
 26. Johnson LA, et al. Gene therapy with human and 
mouse T-cell receptors mediates cancer regres-
sion and targets normal tissues expressing cog-
nate antigen. Blood. 2009;114(3):535–546.
 27. Atkins MB, et al. High-dose recombinant 
interleukin 2 therapy for patients with meta-
static melanoma: analysis of 270 patients 
treated between 1985 and 1993. J Clin Oncol. 
1999;17(7):2105–2116.
Supplemental Material for
Targeting human melanoma neoantigens
by T cell receptor gene therapy
Matthias Leisegang, Thomas Kammertoens, Wolfgang Uckert, Thomas Blankenstein
Index of Supplemental Material
Methods 2
Additional References 9
Supplemental Figure 1 - Cytotoxicity of 14/35-transduced human PBL and mouse HHD T 
cells against R24C- and R24L-expressing cancer cells.
11
Supplemental Figure 2 - Native CDK4 expression in human melanoma cells is lower than 
transgenic CDK4 expression in mouse MC703 cells.
12
Supplemental Figure 3 - MHC I expression on lymphocytes of HHD-transgenic mice is low. 13
Supplemental Figure 4 - MC703 cells expressing high amounts of R24C and R24L peptide 
are similarly recognized by 14/35-transduced HHD T cells in vitro.
14
Supplemental Figure 5 - 14/35-transduced HHD T cells are better stimulated by R24L than 
R24C at low target cell density and by using minigenes encoding multiple epitopes.
15
Supplemental Figure 6 - The anti-tumor response of 14/35-TE cells is CD8-restricted. 16
Supplemental Table 1 - Summary of animal experiments 17
1
Methods
Isolation of TCR genes and construction of retroviral vector plasmids
The patient-derived T cell clone 14/35 has been described (7) and was kindly provided by Thomas 
Wölfel (University  Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany). 
TCR sequences of 14/35 (TRAV20-CAVQSGTSGSRLTF-TRAJ58, TRBV9-CASSVVAGFNEQFF-
TRBJ2-1) and DMF5 (19) were determined and integrated in pMP71-PRE (28) as described (11). The 
high affinity  tyrosinase-specific TCR T58 (11) was used as control (anti-TYR). Genes of human CDK4 
harboring the mutations R24C (codon 24: TGT) or R24L (codon 24: CTT) were synthesized by 
GeneArt (Life Technologies, Carlsbad, CA, USA). Human genes encoding full length CDK4-R24C, 
CDK4-R24L or tyrosinase (11) were ligated into pMP71-i-GFP (29) via Eco72I restriction site as 
described (30) to generate the retroviral vector plasmids pMP71-R24C-i-GFP, pMP71-R24L-i-GFP and 
pMP71-TYR-i-GFP. Fusion constructs of trimer minigenes (ACDPHSGHFV-AAY (ACD), 
ALDPHSGHFV-AAY (ALD), AAGIGILTV-AAY (AAG), ELAGIGILTV-AAG (ELA) or 
YMDGTMSQV-AAY (YMD)) and GFP were designed as previously described (31), generated by 
GeneArt and integrated into pMP71-PRE (pMP71-ACD-GFP, pMP71-ALD-GFP, pMP71-AAG-GFP, 
pMP71-ELA-GFP, pMP71-YMD-GFP).
Cell lines
Plat-E packaging cells (32) and 293T (ATCC: CRL-11268, American Type Culture Collection, 
Manassas, VA, USA) were cultured in Dulbecco's modified Eagles medium supplemented with 10% 
heat-inactivated fetal calf serum (FCS, PAN Biotech, Aidenbach, Germany) and 100 IU/ml penicillin, 
streptomycin. The selection culture medium of Plat-E cells contained 10 µg/ml blasticidin and 1 µg/ml 
puromycin (Sigma-Aldrich, St. Louis, MO, USA). T2 cells (ATCC: CRL-1992) and the melanoma cell 
lines SKMEL-29.1 (SKMEL-29) (33), WM-902B (9) (ESTDAB-085, purchased from European 
2
Searchable Tumor Cell Bank and Database (University  Tübingen, Tübingen, Germany)), SKMEL-37 
(34, 35) and 624MEL-38 (36) were cultured in cell medium (CM, RPMI 1640 supplemented with 10% 
FCS, 100 IU/ml penicillin-streptomycin, 1 mM sodium pyruvate, 1x non-essential amino acids, 50 µM 
2-mercaptoethanol). WM-902B+A2 is a transfectant of WM-902B, generated by transduction with 
retroviral vectors encoding HLA-A2 and GFP as described (37). Unless otherwise indicated, reagents 
were purchased from Invitrogen (Life Technologies).
Generation of retrovirus supernatant
To produce amphotropic murine leukemia virus (MLV)-pseudotyped retroviruses, 293T cells were 
transiently  transfected with the corresponding retrovirus construct and plasmids encoding Moloney 
MLV gag/pol genes (pcDNA3.1-MLVg/p, provided by Christopher Baum (Hannover Medical School, 
Hannover, Germany)) and the MLV-10A1 env gene (pALF-10A1 (38)). 293T cells were transfected 
with 18 µg DNA (6 µg of each plasmid) by calcium phosphate precipitation. Ecotropic retroviruses 
encoding the TCRs 14/35, DMF5 or T58 were obtained after transient transfection of Plat-E cells with 
only retroviral vector plasmids. 48 h after transfection, 3 ml of virus supernatant were harvested, 
filtrated and used for transduction.
Mice
HHD mice were provided by François A. Lemonnier (Institute Pasteur, Paris, France) and have been 
described (13). HHD and B6.129S7-Rag1tm1Mom/J mice were crossed to obtain HHDxRag-/- mice 
(B6.Cg-Tg(HLA-A/H2-D/B2M)1Bpe H2-D1tm1Bpe B2mtm1Unc Rag1tm1Mom/Luck). Offspring were 
genotyped as described (39) and samples of peripheral blood were analyzed for presence of mature 
lymphocytes (anti-mouse CD45R).
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MC703 cells
MC703 fibrosarcoma cells were generated by subcutaneous injection of 50 µg 3'-methylcolanthrene 
(Sigma Aldrich) in 100 µl sesame oil into the left  flank of a 12-week-old female HHD mouse. 135 days 
later at a size of 400 mm3 the tumor was excised, cells were cultured in CM, cloned by limited dilution 
and a single clone was selected based on HHD expression. 5x104 MC703 cells were transduced with 
viruses containing genes of tumor antigens twice by spinoculation (800 x g, 90 min, 32 °C) in 24-well 
plates using 1 ml virus supernatant. Bulk cultures were expanded and either enriched by preparative 
FACS using GFP as a marker (MC703-ACD, MC703-ALD, MC703-AAG, MC703-ELA, MC703-
YMD) or clones were generated by limiting dilution cloning (MC703-R24C, MC703-R24L, MC703-
TYR). Expression of antigen and HHD in MC703 cells was analyzed by  flow cytometry and co-
cultures with 14/35- , DMF5- and T58-engineered HHD T cells.
TCR gene transfer into primary T cells
Spleen cells were isolated from HHD mice and erythrocytes were lysed by ammonium chloride 
treatment. Cells were incubated in CM  supplemented with 1 µg/ml anti-mouse CD3, 0.1 µg/ml anti-
mouse CD28 antibodies (both BD Biosciences (BD), Franklin Lakes, NJ, USA) and 10 IU/ml human 
IL-2 (Proleukin S, Novartis, Basel, Switzerland) at a concentration of 2x106/ml. On the following day, 
1x106 cells were transduced by spinoculation in 24-well non-tissue culture-treated plates pre-coated 
with 12.5 µg/ml RetroNectin (TaKaRa, Otsu, Japan) and virus particles (3200 x g, 90 min, 4 °C) in 1 
ml CM  supplemented with 10 IU/ml IL-2 and 4x105 mouse T-Activator beads (Life Technologies). A 
second transduction was performed on the following day by spinoculation with 1 ml virus supernatant 
(+ 10 IU/ml IL-2). T cells were expanded in CM (+ 50 ng/ml IL-15 (Miltenyi Biotec, Bergisch 
Gladbach, Germany)) for 3 (ATT) or 10 days (co-cultures), respectively. Human PBMCs were isolated 
from healthy  donors by ficoll gradient centrifugation. Initial stimulation was performed at a 
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concentration of 1x106 PBMCs per well and 1 ml of CM (+ 100 IU/ml IL-2) for 72 h in non-tissue 
culture-treated 24-well plates, coated with 5 µg/ml anti-human CD3 and 1 µg/ml anti-human CD28 
antibodies (BD). Human T cells were transduced by  spinoculation at day 2 after isolation by  adding 1 
ml amphotropic virus supernatant  supplemented with 4 µg/µl protamine sulfate (Sigma Aldrich) and 
IL-2 (100 IU/ml). On the next day, a second transduction was performed on RetroNectin-coated 6-well 
plates, which were pre-coated with 3 ml virus supernatant. Cells were expanded in CM  (+ 100 IU/ml 
IL-2). After 10 days, the cells were rested for 2 days (10 IU/ml IL-2).
Tumor challenge and adoptive T cell transfer
3-5x106 tumor cells were subcutaneously injected in 100 µl PBS into the left flank of HHDxRag-/- mice 
(12-20 weeks old, female or male). Tumor growth was analyzed 2-3 times a week by determination of 
tumor volume by caliper measurements according to π/6 x (abc). On the day of T cell transfer, mice 
were ranked by tumor size and sequentially allocated to treatment groups to ensure equal average 
tumor sizes between groups. Mice were treated by adoptive transfer of TCR-engineered HHD T cells 
earliest 3-5 weeks after tumor cell injection when tumors were established. HHD T cells were analyzed 
for expression of CD8, 14/35 (TCRvβ1), DMF5 (A2/Kb:ELA) and T58 (TCRvβ23) by flow cytometry 
and intravenously injected in 100 µl PBS (adjusted to 1x106 CD8+TCR+ HHD T cells per mouse) 3 
days after transduction. Examiners were not blinded with respect to treatment groups. Mice were 
sacrificed when either tumors reached the maximum permitted size or if due to tumor burden the 
overall health-condition was poor. Animals were excluded from analysis, if they died due to reasons 
unrelated to tumor burden.
T cell analysis
5x104 TCR-engineered HHD T cells (14/35, DMF5, T58) or TCR-engineered human PBLs (14/35, 
T58) were co-cultured at an E:T ratio of 1:1 for 24 h with indicated target cells in 200 µl CM in 96-well 
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round bottom plates. Untransduced HHD T cells or human PBLs served as controls. CD8 and CD4 
subpopulations of 14/35-transduced HHD T cells were separated using magnetically-labeled antibodies 
and MACS (Miltenyi Biotech, following manufacturer's protocol). For target cell titration, graded 
amounts of MC703-R24C, -R24L, -ACD and -ALD cells (ranging from 1.25x104 - 98) were diluted in 
5x104 unmodified MC703 tumor cells and incubated with 5x104 effector cells. For peptide titration, 
TCR-engineered human PBLs were incubated with T2 cells in presence of graded amounts of peptide 
(ACD (ACDPHSGHFV), ALD (ALDPHSGHFV), ARD (ARDPHSGHFV), Biosyntan, Berlin 
Germany). Unloaded T2 cells served as control. Supernatants of co-cultures were analyzed for IFN-γ or 
IL-2 content by enzyme-linked immunosorbent assay (ELISA, BD). For TCR-independent maximal 
stimulation of effector cells, 1 µM ionomycin (Merck, Darmstadt, Germany) and 5 ng/ml phorbol-12-
myristate-13-acetate (PMA, Promega, Fitchburg, WI, USA) were used. Cytotoxic activity of 2x105 
14/35-transduced human PBL or HHD T cells was analyzed by 16 h incubation with target cells (E:T 
ratio of 2:1) in 200 µl CM  in presence of 1 µg CD107a-specific antibodies (anti-human: H4A3; anti-
mouse: 1D4B, both Brilliant Violet 421, BioLegend, San Diego, CA, USA) and subsequent FACS 
analysis using MACSQuant (Miltenyi Biotec). To detect T cell numbers in peripheral blood, 50 µl 
peripheral blood were incubated with Fc block (BD) and indicated antibodies. Erythrocytes were lysed 
by ammonium chloride treatment, samples were washed in PBS and measured using FACSCanto II 
(BD). Total cells in each sample were measured to determine total cell counts per 50 µl blood. 
Numbers of CD8+ and CD8- CD3+TCRvβ+ lymphocytes were calculated per ml blood.
Cytokine concentrations in peripheral blood
Peripheral blood was collected from vena facialis, cell-free supernatants were obtained by 
centrifugation and stored at -80 °C until analyzed using cytometric bead array (CBA, Mouse Th1/Th2/
Th17 Cytokine Kit, BD) following the manufacturer's instructions.
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Flow cytometry and antibodies
Unless stated otherwise, cells or blood samples were incubated with 50 µl PBS containing 1 µg of 
indicated anti-mouse antibodies: CD3 (145-2C11, allophycocyanin (APC) or fluorescein isothiocyanate 
(FITC), BioLegend), CD8 (53-6.7, Brilliant Violet 421 or APC, BioLegend), CD45R (RA3-6B2, PE, 
BD). Anti-human TCRvβ-specific antibodies were used to analyze expression of TCRs 14/35 and T58: 
TCRvβ1 (14/35, BL37.2, PE, Beckman Coulter, Brea, CA, USA), TCRvβ23 (T58, AF23, PE, Beckman 
Coulter). Expression of TCR DMF5 on HHD T cells was analyzed using chimeric A2/Kb pentamers 
loaded with ELAGIGILTV peptide (PE, ProImmune, Oxford, UK). TCR-engineered human PBL were 
analyzed using anti-mouse TCRcβ (H57-597, APC, BD), anti-human CD8 (HIT8a, PE, BD) and anti-
human CD3 (UCHT1, FITC, BD) antibodies. Anti-human HLA-A2 (BB7.2, Alexa Fluor 647, AbD 
Serotec, Bio-Rad, Hercules, CA, USA) and isotype control antibody (mouse IgG2b, Alexa Fluor 647, 
AbD Serotec) were used to detect expression of HHD or HLA-A2. Anti-mouse H-2Kb (AF6-88.5, PE, 
BD) and isotype control antibody  (mouse IgG2a, κ, PE, BD) were used to detect expression of H-2Kb. 
1 µg Fc block was added to samples of peripheral blood 10 min prior addition of specific antibodies 
(anti-mouse CD16/CD32, 2.4G2, BD). Erythrocytes were lysed by ammonium chloride treatment 
(when necessary), samples were washed in PBS and acquired using MACSQuant or FACSCalibur 
(BD). 1 µM SYTOX Blue were used for live/dead cell discrimination. Data analysis was performed 
using FlowJo software (TreeStar, Ashland, OR, USA).
Analysis of CDK4 mutations in human melanoma cell lines
Total RNA was isolated from cultured tumor cells (SKMEL-29, WM-902B, SKMEL-37, 624MEL-38) 
and complementary DNA (cDNA) was synthesized using 1 µg total RNA as template (SuperScript II 
Reverse Transcriptase (Life Technologies), following manufacturer's protocol). Sequences of the CDK4 
gene were amplified by PCR (5'-tgg tgt cgg tgc cta tgg ga-3' (sense), 5'-ggc caa agt  cag cca gct 
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tga-3' (antisense)), purified by gel electrophoresis (Invisorb Fragment Cleanup, Stratec) and analyzed 
by sequencing (Eurofins Genomics).
Western blot analysis of CDK4 in human melanoma cell lines and MC703 cells
Western Blot analysis was performed as previously  described (40). Briefly, 30 µg of tumor cell lysates 
(SKMEL-29, WM-902B, SKMEL37, 624MEL-38, MC703, MC703-R24C and MC703-R24L) were 
separated on a 12% SDS-polyacrylamid gel and proteins were transferred to a nitrocellulose membrane. 
The membrane was incubated in blocking and wash buffer and probed with polyclonal anti-human 
CDK4 (host: rabbit, LS-C290866/66675, 0.5 µg/ml, LifeSpan BioSciences, Seattle, WA, USA) and 
secondary  HRP-coupled goat  anti-rabbit antibodies (Santa Cruz Biotechnologies, Dallas, TX, USA). 
Chemiluminescence was captured on a X-ray film after adding Luminol substrate (both: Santa Cruz 
Biotechnologies). The membrane was stripped from antibodies and a second detection using an anti-β-
actin antibody (AC-15, HRP-coupled, cross-reactive to human and mouse β-actin, Sigma Aldrich) was 
performed to control that equal amounts of protein were loaded.
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Supplemental Figure 1 - Cytotoxicity of 14/35-transduced human PBL and mouse HHD T cells 
against R24C- and R24L-expressing cancer cells.
(A) 14/35-transduced human PBL or (B) mouse HHD T cells were incubated with indicated target cells 
in presence of CD107a-specific antibodies. Co-cultured cells were analyzed by  flow cytometry and the 
mean fluorescence intensity (MFI) of bound CD107a antibodies is shown for either 14/35+ or 14/35- 
CD3+CD8+ cells. Data are means of duplicates ± mean deviation. Two independent experiments were 
performed.
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Supplemental Figure 2 - Native CDK4 expression in human melanoma cell lines is lower than 
transgenic CDK4 expression in mouse MC703 cells.
Lysates (30 µg of protein) of indicated cancer cells were analyzed by Western blot using polyclonal 
human CDK4-specific antibodies. Transfer of equal amounts of protein was confirmed by detecting β-
actin. Results are representative for three independent experiments.
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Supplemental Figure 3 - MHC I expression on lymphocytes of HHD-transgenic mice is low.
Peripheral blood of C57BL/6, HHDxRag+/- or humans was incubated with anti-human-HLA-A2 (top) 
or anti-mouse-H-2Kb antibodies (bottom). MHC expression on lymphocytes was analyzed by flow 
cytometry. One representative analysis of C57BL/6 (n=3), HHDxRag+/- (n=3) or humans (n=2) is 
shown.
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Supplemental Figure 4 - MC703 tumor cells expressing high amounts of R24C and R24L peptide are 
similarly recognized by 14/35-transduced HHD T cells in vitro.
(A) MP71 vector encoding trimeric minigenes of peptide (Pep)-AAY fused to GFP (LTR: long terminal 
repeat, PRE: post-transcriptional regulatory element of woodchuck hepatitis virus). (B) Antigen (GFP) 
expression in MC703-ACD, -ALD and -YMD cells. (C) IFN-γ secretion of 14/35-engineered HHD T 
cells after co-culture with MC703-ACD, -ALD and -YMD tumor cells. HHD T cells either unmodified 
or expressing a tyrosinase-specific TCR (anti-TYR) were used as control. Means of duplicates ± mean 
deviation, representative for two independent experiments. nd: not detectable.
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Supplemental Figure 5 - 14/35-transduced HHD T cells are better stimulated by R24L than R24C at 
low target cell density and by using minigenes encoding multiple epitopes.
Titrated amounts of MC703 cells expressing full length genes of mutant CDK4 (R24C, R24L) or trimer 
minigenes encoding R24C and R24L epitopes (ACD, ALD) were mixed with 5x104 unmodified 
MC703 cells. The percentage of antigen-expressing tumor cells in the target cell population is given on 
the x-axis (1.5% correspond to ~800 antigen-expressing MC703 cells). IFN-γ secretion of 14/35-
engineered HHD T cells after co-culture with target cells was set in relation to the maximum amount of 
IFN-γ secreted. HHD T cells either unmodified or expressing a tyrosinase-specific TCR (anti-TYR) 
showed no IFN-γ secretion after co-culture with indicated target cell populations (not shown). Data are 
means of duplicates ± mean deviation, representative for two independent experiments.
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Supplemental Figure 6 - The anti-tumor response of 14/35-TE cells is CD8-restricted.
(A) CD8 expression of 14/35-transduced HHD T cells before and 7 days after adoptive transfer into a 
MC703-R24L tumor-bearing HHDxRag-/- mouse (shown in Figure 2B). (B, C) Total numbers of CD8+ 
and CD8- 14/35-TE in blood during ATT of mice bearing MC703-R24L (B, n=7) or MC703-R24C 
tumors (C, n=5). Data correspond to analyses shown in Figure 2A, B, E and F. (D) Percentages of 
CD4- and TCRvβ1-expressing 14/35-transduced HHD T cells in cultures enriched for either CD8 or 
CD4 expression. (E, F) IFN-γ (E) and IL-2 (F) secretion of 14/35-engineered HHD T cells shown in 
panel D after co-culture with indicated target cells. T cells were incubated with PMA and ionomycin 
for TCR-independent stimulation (Max). Means of duplicates ± mean deviation, representative for 
three independent experiments. nd: not detectable.
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Supplemental Table 1 - Summary of animal experiments
Designation ATT Regression Relapse
MC703- Time (d) Tumor size (mm3) (d after ATT) (d after ATT)
R24C 24 220 - -
R24C 24 207 - -
R24C 24 165 - -
R24C 24 118 - -
R24C 24 359 - -
Mean 24 214 - -
R24L 31 636 7 22
R24L 31 242 7 22
R24L 31 264 7 34
R24L 34 754 7 28
R24L 34 490 7 21
R24L 34 1106 7 18
R24L 34 749 7 21
Mean 33 606 7 24
ACD 27 126 - -
ACD 27 242 - -
ACD 27 220 - -
ACD 27 424 - -
ACD 27 242 - -
ACD 27 586 - -
ACD 28 377 - -
Mean 27 317 - -
ALD 27 436 7 -
ALD 27 282 7 -
ALD 27 157 7 -
ALD 27 330 7 -
ALD 27 282 7 -
ALD 28 402 7 -
Mean 27 315 7 -
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Designation ATT Regression Relapse
MC703- Time (d) Tumor size (mm3) (d after ATT) (d after ATT)
AAG 26 264 - -
AAG 26 205 - -
AAG 26 28 - -
AAG 26 298 - -
AAG 26 323 - -
Mean 26 224 - -
ELA 26 205 11 -
ELA 26 352 9 -
ELA 26 198 9 -
ELA 26 226 9 -
Mean 26 245 10 -
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